Male Hypogonadism Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global market for male hypogonadism is poised for significant growth, driven by increasing awareness and the availability of effective treatment options. Lack of sex hormones, generally referred to as male hypogonadism, leads to several health risks such as osteoporosis and heart disease due to the thinning of bones. The market comprises several patented brands with high market penetration, supported by a growing geriatric population and rising incidences of rheumatoid arthritis and obesity.

Mounting Cases of Testosterone Deficiency

A key factor underpinning the prevalence of male hypogonadism globally is the mounting cases of testosterone deficiency in men. Several governments worldwide are actively driving awareness about hypogonadism treatment methods, including testosterone replacement therapy (TST), among patients. This initiative aims to mitigate the exacerbation of chronic conditions associated with low testosterone levels and disorders related to the hypothalamic-pituitary-gonadal axis.

The Impact of Testosterone Replacement Therapy

The advent of TST has enabled a reduction in the number of male hypogonadism cases to a certain extent. With growing awareness about the treatment among people, the market is expected to gain momentum in the near future. Additionally, the availability of selective androgen receptor modulators (SARMs) is anticipated to accelerate market expansion. The development and free availability of SARMs have provided better treatment procedures for patients with androgen deficiencies, contributing to market growth.

Steady Market Expansion

According to a new report by Fairfield Market Research, the global male hypogonadism market is projected to reflect steady expansion during the period from 2017 to 2026. The market is forecast to surpass significant revenue milestones by the end of 2026, driven by various factors, including increased awareness and the introduction of advanced treatment options.

Topical Gels to Dominate Market Revenue

Based on drug type, topical gels will continue to account for the largest revenue share in the global male hypogonadism market. Available in a semi-liquid state, topical gels comprise an active ingredient that can be applied locally, offering maximum efficacy. The ease of application and removal has further boosted their demand among patients. Conversely, transdermal patches are expected to account for the smallest revenue share during the forecast period.

North America Leading the Market

In North America, a relatively higher prevalence of chronic diseases is observed due to lower testosterone levels in the region’s male population. This has created a high demand for testosterone replacement therapy, contributing significantly to the region’s revenue share in the male hypogonadism market. North America will remain dominant in the market in terms of revenues and is also projected to exhibit the highest compound annual growth rate (CAGR) through 2026.

Key Research Findings

Fairfield Market Research's report highlights several key findings:

• Therapy Type: Testosterone replacement therapy will continue to lead the global male hypogonadism market in terms of revenues.
• Disease Type: Klinefelter’s syndrome will account for a relatively larger revenue share during the forecast period.

Market Competition and Strategic Alliances

The nature of the global male hypogonadism market is highly competitive, characterized by the presence of many small and large suppliers. Occasional competition eruptions are observed from local manufacturers in various countries. New companies are entering the market as treatment developments and innovations pave numerous opportunities for these players. Strategic alliances will remain key among vendors to produce and market drugs worldwide and increase their market reach.

Key Players in the Market

The report identifies several key players in the global male hypogonadism market, including IBSA Institut Biochimque, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company Ltd., Ferring, Allergan Plc., Merck & Co. Inc., Bayer AG, Finox Biotech, AbbVie Inc., Endo International Plc., Laboratories Genevrier, and AstraZeneca Plc.

Global Male Hypogonadism market is Segmented as Below:

By Therapy:

• Testosterone Replacement Therapy
• Gonadotropin Replacement Therapy

By Drug Type:

• Topical Gels
• Injectables
• Transdermal Patches
• Others

By Disease Type:

• Klinefelter's Syndrome
• Pituitary Adenomas
• Kallmann Syndrome
• Other Types

By Region:

• North Americ
• Latin America
• Europe
• Japan
• APEJ
• MEA

This product will be delivered within 1-3 business days.